Rituxan data in indolent NHL

Idec (IDPH) and partner Genentech (DNA) said that in a study of 188 eligible patients with chemotherapy-naive and relapsed indolent non-Hodgkin's lymphoma (NHL), an initial four-week course of Rituxan...